Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 马应龙药业集团股份有限公司是一家涉足于药品制造、药品研发、药品批发零售、连锁医院等多个领域的上市公司.其主要产品和服务有治痔类产品、医药零售批发和医院诊疗等.公司是经商务部首批认定的中华老字号企业,生产功能齐全,可生产剂型超过30种,可供生产的国药准字号药品超过300种,拥有独家品种20多个,共有18个国药准字号品种入选《国家基本药物目录》,37个品种入选《国家医保目录》,其中马应龙麝香痔疮膏、麝香痔疮栓、龙珠软膏、马应龙八宝眼膏为公司独家产品.生产设施先进,主要品种生产流水线及配套设施的技术水平已处于国内领先水平.在世界品牌实验室、世界经理人周刊联合评估的2010年"中国最具价值品牌500强"排行榜中,马应龙名列第210位,品牌价值达到了43.21亿元.2006年,马应龙荣获国家工商总局认定的"中国驰名商标",成为中国治痔领域唯一的"中国驰名商标"。
Main Business 中西药制造
Legal Representative 陈平
Top Executives
董事长：陈平
董事：夏有章,黄其龙,徐飚,刘平安,周岳
独立董事：张勇慧,齐珺,毛鹏
Top 5 Shareholder
Shareholder name Nature Holding Date
中国宝安集团股份有限公司流通A股29.27%31/03/2024
武汉商贸集团有限公司流通A股5.21%31/03/2024
中信银行股份有限公司－交银施罗德新生活力灵活配置混合型证券投资基金流通A股3.36%31/03/2024
基本养老保险基金八零七组合流通A股1.48%31/03/2024
赵福安流通A股1.37%31/03/2024
Company Secretary 马倩
Solicitors 湖北得伟律师事务所
Auditors 武汉众环会计师事务所有限责任公司
Tel No 027-87389583;027-87291519
Fax No 027-87291724
Website www.mayinglong.cn
Email stock@my11582.com;maqian1582@sohu.com;gyp1582@163.com
Company Address
Register: 湖北省武汉市武昌南湖周家湾100号
Office: 湖北省武汉市武昌南湖周家湾100号
Listing Date 17/05/2004
Shares Capital
Shares Capital: 431,053,891
Total A Share: 431,053,891
Listed A Share: 430,307,016
Non-tradable A Share: 746,875
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.030
DPS(RMB)* ¥ 0.400
NBV Per Share(RMB)* ¥ 8.672
Market Capitalization(RMB) 11.967B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.